Nov. 6, 2024 — The CRISPR tool is capable of repairing the genetic defect responsible for the immune disease chronic granulomatous disease. However, researchers have now shown that there is a ...
In Vivo Medicines Editas Medicine and Genevant Sciences entered into a collaboration and nonexclusive license agreement to combine Editas’ CRISPR Cas12a genome editing systems with Genevant’s ...